肿瘤科指南

订阅

MedSci主页 / 所有栏目 / 肿瘤科指南

2021 SITC实践指南：尿路上皮癌的免疫治疗

2021-07-09 肿瘤免疫治疗学会 J Immunother Cancer

尿路上皮癌

本文主要针对尿路上皮癌的免疫治疗提供指导建议。

中文标题：

2021 SITC实践指南：尿路上皮癌的免疫治疗

英文标题：

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer

发布机构：

肿瘤免疫治疗学会

发布日期：

2021-07-09

简要介绍：

2021年7月，肿瘤免疫治疗学会(SITC)发布了尿路上皮癌的免疫治疗指南，尿路上皮癌（包括膀胱，尿道和肾盂）的许多免疫疗法已经被开发和采用，为了使这些免疫疗法对患者的预后产生积极影响，药物的最佳选择和治疗计划，特别是结合现有的治疗模式非常重要。本文主要针对尿路上皮癌的免疫治疗提供指导建议。

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 SITC实践指南：尿路上皮癌的免疫治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=abb681c002203852, title=2021 SITC实践指南：尿路上皮癌的免疫治疗, enTitle=Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer, guiderFrom=J Immunother Cancer, authorId=0, author=, summary=本文主要针对尿路上皮癌的免疫治疗提供指导建议。, cover=https://img.medsci.cn/20211013/1634102406454_5579292.jpg, journalId=0, articlesId=null, associationId=1167, associationName=肿瘤免疫治疗学会, associationIntro=null, copyright=0, guiderPublishedTime=Fri Jul 09 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">2021年7月，肿瘤免疫治疗学会(SITC)发布了尿路上皮癌的免疫治疗指南，尿路上皮癌（包括膀胱，尿道和肾盂）的许多免疫疗法已经被开发和采用，为了使这些免疫疗法对患者的预后产生积极影响，药物的最佳选择和治疗计划，特别是结合现有的治疗模式非常重要。本文主要针对尿路上皮癌的免疫治疗提供指导建议。</span></p>, tagList=[TagDto(tagId=24887, tagName=尿路上皮癌)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=26, categoryName=泌尿外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=24887, guiderKeyword=尿路上皮癌, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4442, appHits=87, showAppHits=0, pcHits=1369, showPcHits=4355, likes=0, shares=9, comments=6, approvalStatus=1, publishedTime=Wed Oct 13 13:22:42 CST 2021, publishedTimeString=2021-07-09, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Wed Oct 13 13:22:25 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Thu Jan 04 23:31:05 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 SITC实践指南：尿路上皮癌的免疫治疗.pdf)])
2021 SITC实践指南：尿路上皮癌的免疫治疗.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1071347, encodeId=c65010e13471c, content=前移，联合, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83be5719217, createdName=ms9000001664046218, createdTime=Thu Nov 18 10:43:45 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060565, encodeId=bcc0106056536, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d325618006, createdName=ms9000000642905514, createdTime=Thu Oct 14 21:45:58 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060316, encodeId=59df10603162a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Oct 14 07:04:05 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060145, encodeId=ebac10601450a, content=不错，主流趋势, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd1c2872998, createdName=wmh49855, createdTime=Wed Oct 13 15:14:53 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060123, encodeId=8ec11060123fc, content=免疫治疗越来越好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:10:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-11-18 ms9000001664046218

    前移，联合

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1071347, encodeId=c65010e13471c, content=前移，联合, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83be5719217, createdName=ms9000001664046218, createdTime=Thu Nov 18 10:43:45 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060565, encodeId=bcc0106056536, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d325618006, createdName=ms9000000642905514, createdTime=Thu Oct 14 21:45:58 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060316, encodeId=59df10603162a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Oct 14 07:04:05 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060145, encodeId=ebac10601450a, content=不错，主流趋势, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd1c2872998, createdName=wmh49855, createdTime=Wed Oct 13 15:14:53 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060123, encodeId=8ec11060123fc, content=免疫治疗越来越好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:10:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-14 ms9000000642905514

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1071347, encodeId=c65010e13471c, content=前移，联合, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83be5719217, createdName=ms9000001664046218, createdTime=Thu Nov 18 10:43:45 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060565, encodeId=bcc0106056536, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d325618006, createdName=ms9000000642905514, createdTime=Thu Oct 14 21:45:58 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060316, encodeId=59df10603162a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Oct 14 07:04:05 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060145, encodeId=ebac10601450a, content=不错，主流趋势, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd1c2872998, createdName=wmh49855, createdTime=Wed Oct 13 15:14:53 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060123, encodeId=8ec11060123fc, content=免疫治疗越来越好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:10:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-14 微探

    学习学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1071347, encodeId=c65010e13471c, content=前移，联合, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83be5719217, createdName=ms9000001664046218, createdTime=Thu Nov 18 10:43:45 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060565, encodeId=bcc0106056536, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d325618006, createdName=ms9000000642905514, createdTime=Thu Oct 14 21:45:58 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060316, encodeId=59df10603162a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Oct 14 07:04:05 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060145, encodeId=ebac10601450a, content=不错，主流趋势, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd1c2872998, createdName=wmh49855, createdTime=Wed Oct 13 15:14:53 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060123, encodeId=8ec11060123fc, content=免疫治疗越来越好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:10:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 wmh49855

    不错，主流趋势

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1071347, encodeId=c65010e13471c, content=前移，联合, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=83be5719217, createdName=ms9000001664046218, createdTime=Thu Nov 18 10:43:45 CST 2021, time=2021-11-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060565, encodeId=bcc0106056536, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7d325618006, createdName=ms9000000642905514, createdTime=Thu Oct 14 21:45:58 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060316, encodeId=59df10603162a, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Oct 14 07:04:05 CST 2021, time=2021-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060145, encodeId=ebac10601450a, content=不错，主流趋势, beContent=null, objectType=guider, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd1c2872998, createdName=wmh49855, createdTime=Wed Oct 13 15:14:53 CST 2021, time=2021-10-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060123, encodeId=8ec11060123fc, content=免疫治疗越来越好了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d16d2301166, createdName=旭日东升a, createdTime=Wed Oct 13 14:10:55 CST 2021, time=2021-10-13, status=1, ipAttribution=)]
    2021-10-13 旭日东升a

    免疫治疗越来越好了

    0

相关指南

膀胱浸润性尿路上皮癌PD-L1（SP263）免疫组织化学检测病理专家共识

中华医学会病理学分会 · 2020-11-30

拓展阅读

膀胱浸润性尿路上皮癌PD-L1（SP263）免疫组织化学检测病理专家共识

中华医学会病理学分会 · 2020-11-30

尿路上皮癌抗体偶联药物临床应用安全共识(第一版)

中国医疗保健国际促进交流会泌尿健康促进分会 · 2022-06-16

尿路上皮癌抗体偶联药物临床应用安全共识（第1版）

中国医疗保健国际交流促进会 · 2022-08-30

2024 拉丁美洲共识：转移性/局部晚期尿路上皮癌患者的评估和治疗

国外肿瘤科相关专家小组（统称） · 2024-01-10

2024 ESMO 晚期尿路上皮癌一线治疗临床实践指南临时更新

欧洲肿瘤内科学会(ESMO,European Society for Medical Oncology) · 2024-03-13